WuXi Biologics and Vir Biotechnology, have entered a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The companies will work on the clinical development, manufacturing, and commercialization of Vir’s antibodies. WuXi Biologics will conduct cell-line development, process and formulation develop...